The consortium, led by the Broad Institute of Massachusetts Institute of Technology and Harvard University, includes pharmaceutical companies and nonprofit research organizations. It is focused on creating and sharing a large public cell imaging dataset to help scientists determine the mechanism of action of new therapeutics in preclinical research stages.

When completed, the dataset will feature information from over 1 billion cells responding to more than 140,000 small molecule and genetic perturbations.

Consortium scientists will use PerkinElmer PhenoVue kits, which provide validated, preoptimized fluorescent probes, to save time and resources.

PerkinElmer to acquire Nexcelom for $260M
PerkinElmer has entered into an agreement to acquire life sciences instrumentation firm Nexcelom Bioscience for $260 million, a deal that is expected...

Researchers innovate drug discovery screening techniques
Researchers from around the globe gathered to discuss innovations in laboratory techniques such as phenotypic profiling and flow cytometry for drug discovery...